Evotec AG (NASDAQ:EVO) Short Interest Update

Evotec AG (NASDAQ:EVO) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 251,399 shares, a decline of 68.3% from the December 15th total of 793,290 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 341,984 shares, the short-interest ratio is presently 0.7 days. Based on an average trading volume of 341,984 shares, the short-interest ratio is presently 0.7 days. Currently, 0.1% of the shares of the stock are sold short.

Institutional Investors Weigh In On Evotec

Several hedge funds have recently bought and sold shares of EVO. Valeo Financial Advisors LLC purchased a new position in Evotec during the 2nd quarter valued at about $43,000. BNP Paribas Financial Markets grew its position in Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares in the last quarter. Bank of America Corp DE increased its stake in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after buying an additional 9,289 shares during the period. Thrivent Financial for Lutherans purchased a new stake in Evotec in the 3rd quarter worth approximately $53,000. Finally, UMB Bank n.a. acquired a new stake in shares of Evotec during the 2nd quarter valued at $56,000. 5.81% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Evotec from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Evotec in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $7.00.

Evotec Stock Down 2.2%

Shares of EVO stock traded down $0.08 during trading hours on Thursday, reaching $3.62. 31,126 shares of the stock traded hands, compared to its average volume of 80,394. The company has a quick ratio of 2.03, a current ratio of 2.12 and a debt-to-equity ratio of 0.48. Evotec has a 1-year low of $2.84 and a 1-year high of $4.80. The business has a fifty day moving average price of $3.16 and a 200 day moving average price of $3.61.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.